Paromomycin sulfate

From Wikipedia, the free encyclopedia

Paromomycin sulfate
Systematic (IUPAC) name
(2R,3S,4R,5R,6S)-5-amino-6-[(1R,2S,3S,4R,6S)-
4,6-diamino-2-[(2S,3R,4R,5R)-4-[(2R,3R,4R,5R,6S)-
3-amino-6-(aminomethyl)-4,5-dihydroxy-oxan-2-yl]
oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-
3-hydroxy-cyclohexyl]oxy-2-(hydroxymethyl)oxane-3,4-diol
Identifiers
CAS number 1263-89-4
ATC code A07AA06
PubChem 165580
DrugBank ?
Chemical data
Formula C23H47N5O18S 
Mol. mass 615.629 g/mol
Pharmacokinetic data
Bioavailability None
Metabolism None
Half life  ?
Excretion Fecal
Therapeutic considerations
Pregnancy cat.

C(US)

Legal status

Rx only U.S.

Routes Oral, intramuscular

Paromomycin sulfate (brand name Humatin) is a drug that fights intestinal infections such as cryptosporidiosis and amoeba infection, or amoebiasis and was developed as a therapeutic against visceral leishmaniasis by the Institute for OneWorld Health. Paromomycin was granted orphan drug status in 2005[1] and was approved by the Drug Controller General of India in September 2006 for treatment of visceral leishmaniasis.[2]

Paromomycin inhibits protein synthesis by binding to 16S ribosomal RNA.[3]

As of February 5th, 2008, King Pharmaceuticals is discontinuing the sale of Humatin, Paromomycin continues to be available in the United States from another manufacturer. [1]


[edit] References

  1. ^ Institute for OneWorld Health (23 May 2005). "Institute for OneWorld Health Drug Receives “Orphan” Designation From U.S. and European Regulatory Agencies". Press release. Retrieved on 2007-02-10.
  2. ^ Institute for OneWorld Health (8 September 2006). "New cure for deadly visceral leishmaniasis (kala-azar) approved by government of India". Press release. Retrieved on 2007-02-10.
  3. ^ Vicens, Quentin; Eric Westhof (August 2001). "Crystal Structure of Paromomycin Docked into the Eubacterial Ribosomal Decoding A Site". Structure 9 (8): 647–658. doi:10.1016/S0969-2126(01)00629-3. PMID 11587639. 
Languages